Add Formweb to your mobile device
Following is a P and T Committee update (from the July 27th meeting). Starting date for specific programs is 31 July 2017, unless otherwise noted. Please let me know if you have any questions or comments. Don’t forget to check the “New Drug Monitoring Spotlight” section of the website, which provides important monitoring information about newly approved drugs. Also, attached is the updated version of the “Not Stocked, Not Ordered” drug list with the new additions highlighted in red.
Below is the memo with links to the drug monographs, protocols, and formulary documents. Click to access the full P&T packet for this month, or here to access the P&T packet archive.
|
Drug or Drug Class |
Formulary Decision |
Comments |
| niraparib (Zejula) | Non-Formulary | Inpatients may use own supply. Defer initiation until after hospital discharge. |
| ribociclib (Kisqali) | Non-Formulary | Inpatients may use own supply. Defer initiation until after hospital discharge. |
| telotristat ethyl (Xermelo) | Non-Formulary | Inpatients may use own supply. The hospital is unable to stock this medication. |
| olaratumab (Lartruvo) | Formulary, Restricted | Restricted to use in outpatient infusion areas. |
| avelumab (Bavencio) | Formulary, Restricted | Restricted to use in outpatient infusion areas. |
| dasatinib (Sprycel) Update | Reclassified as Non-Formulary | Restricted to use in outpatient infusion areas. |
| codeine & traMADol products | Restricted to Adult Patients | The FDA placed several contraindications based on varying ages and disease states. The Committee approved restricted use to patients ≥ 18 years of age. |
| oxymetazoline cream (Rhofade) | Non-Formulary | Other formulary options are available for rosacea treatment. Inpatients may use own supply. Defer initiation until after hospital discharge. |
| EPINEPHrine Shortage Management | Off-Label Use of IM/SC Product Approved |
EPINEPHrine vials labeled “for IM/SC use” may be administered intravenously. |
| pantoprazole IV (Protonix) Shortage Management | Temporary Therapeutic Interchange Approved |
If no indication present, discuss 1) Unable to tolerate PO meds |
| tranexamic acid Use in OB Hemorrhage | Expanded Use Approved | Tranexamic acid use in OB Hemorrhage was approved in conjunction with the updated Massive Transfusion Protocol for OB/GYN. |
| Massive Transfusion OB/GYN Order Set |
Order Set Approved | Order set to be used as part of the Massive Transfusion Protocol – OB/GYN (MTP OB/GYN). |
| Pharmacist Clarification of Home Medications – Update |
Updates Approved | Home OTC medications added or removed after the physician’s signature on a medication reconciliation list (MRL) may be initiated or discontinued by the pharmacist. Prescription or OTC medications used for symptomatic treatment (i.e., not therapeutic) removed from the MRL may be discontinued automatically by the pharmacist. |